236 results about "Lipid accumulation" patented technology

The invention provides pharmaceutical compositions, methods for the treatment of, and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic syndromes, including hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states. In an additional aspect of the invention, compositions and methods of treatment are calibrated to the ileal brake response to surgical intervention e.g. Roux-en-Y gastric bypass (RYGB)) as both activate the ileal brake, which acts in the gastrointestinal tract and the liver of a mammal to control metabolic syndrome manifestations and thereby reverse or ameliorate the cardiovascular damage (atherosclerosis, hypertension, lipid accumulation, and the like) resulting from progression of metabolic syndrome. The net benefit is the potential to treat all of the common manifestations of metabolic syndrome, including Type 2 diabetes and obesity, with one medicament, which contains glucose as an activation agent for the ileal brake. The ileal brake is the controller for progression of metabolic syndrome, and both RYGB surgery and the oral formulation act beneficially on the metabolic syndrome manifestations via this pathway. Disclosed as well are combination medicaments that act synergistically on the ileal brake and the manifestations of metabolic syndrome.

In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to RYGB surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans.

The present invention provides a culture method for promoting autotrophy microalgae neutral lipid accumulation, wherein microalgae having neutral lipid accumulation metabolism capability at a proliferation later stage is subjected to neutral lipid accumulation culture under a 400-550 nm light wave condition. According to the method, under the premise of proliferation culture of the obtained first step cells to achieve the maximum biomass, microalgae neutral lipid metabolism rapidly responses in a short time through temperature reduction on the microalgae liquid and a synergism effect of the illumination condition so as to achieve a purpose of promotion and increase of the neutral lipid accumulation efficiency and the neutral lipid accumulation amount. The blue filter membrane is a plastic film, and can be subjected to large-scale application and modification. The nitrogen limitation stress condition can be achieved through N/P ratio inversion regulation without a microalgae and media separation process. In addition, the process in the large-scale production can be simplified.

Evidence is emerging that lipid accumulation in the liver and the muscle contributes to insulin resistance in type II diabetes and the metabolic syndrome (1). This has prompted an investigation of the relationship between lipid accumulation in the liver, serum triglyceride levels, and glucose disposal. These studies demonstrate that liver fat positively correlated to fasting triglyceride levels and negatively correlated to glucose diposal (2). Therefore, strategies to prevent lipid accumulation in liver would have therapeutic value for treatment of type II diabetes, metabolic syndrome and non-alcoholic fatty liver disease. The invention described here relates to continuous administration of GLP-1 or its analogs obtained by either gene or cell therapy that results in reduction serum triglycerides and reduction of lipid accumulation in the liver for treatment of type II diabetes, the metabolic syndrome or non-alcoholic fatty liver disease.

The invention generally relates to the use of leptin in the treatment of a leptin-responsive disease or condition in a non-lipodystrophic subject. More particularly, the invention is directed to the use of leptin in the treatment of a fatty liver disease in a non-lipodystrophic subject with a relative leptin deficiency. The invention includes methods for the treatment of nonalcoholic steatohepatitis (NASH), alcoholic fatty liver disease (AFLD), and nonalcoholic fatty liver disease (NAFLD) in a non-lipodystrophic subject. The invention includes the treatment of conditions ranging from ectopic lipid accumulation (steatosis) to cirrhosis.

The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.

The invention discloses a method for promoting chlorella growth and oil accumulation by carrying out co-culture of an alga and a bacterium. The method for promoting chlorella growth and oil accumulation by carrying out co-culture of the algae and the bacterium specifically comprise a step of co-culturing chlorella with Mesorhizobium sp. (a nitrogen-fixing bacterium) in certain proportion, so that,oxygen and extracellular metabolites released by the chlorella during growth process can be consumed by the Mesorhizobium sp. while carbon dioxide is metabolized by the Mesorhizobium sp. for photosynthesis of the chlorella cells; moreover, growth stimulators, including vitamins, glycopeptides and the like, are also released so as to promote growth of the chlorella. In addition, nitrogen-fixing capability of the Mesorhizobium sp. is further utilized so as to realize limited nitrogen supply; and thus, normal growth of the chlorella is ensured with efficient oil production of the chlorella cellsrealized.

The present invention provides methods and compositions for the induction of expression of UCP1 independent of lipid accumulation. The invention, in particular, features methods for converting FGF receptive cells, e.g., preadipocyte cells, into energy consuming cells through FGF-mediated UCP1 expression. The invention further provides methods and compositions for treating metabolic disorders with an FGF receptor agonist, (e.g., an FGF protein, or fragment thereof, a nucleic acid encoding an FGF protein, an FGF mimetic, an anti-FGF receptor agonist antibody, or antigen binding fragment thereof), or a cell contacted with an FGF receptor agonist, including FGF6.

The invention discloses a culture method for efficiently inducing lipid accumulation in Botryococcus braunii, which comprises the following steps of: preparing a culture medium and daily added nutrient solution, culturing the Botryococcus braunii for 10 to 18 days of biomass accumulation, introducing CO2 into the Botryococcus braunii culture solution, regulating the concentration of the added nutrient solution, performing ultrasonic treatment on the Botryococcus braunii culture solution for 1 to 3 times by using an ultrasonic instrument at a certain frequency, spacing 10 seconds each time, and treating 5 to 60 seconds each time to inducing the lipid accumulation in the Botryococcus braunii. For the Botryococcus braunii cultured by the method, the biomass is improved by 1 to 1.5 times, thetotal fat content is improved by 30 to 55 percent, and the growth cycle is shortened by 2 to 3 days. A carbon source is supplemented in a mode of introducing CO2; and in the process of producing the lipid accumulation in the Botryococcus braunii on a large scale, a great amount of CO2 waste gas generated in the industrial production process is absorbed, and the method has significance for saving energy, reducing emission and protecting environment.

A method of producing a phytomedicinal therapeutic for the prevention and control of a disease selected from the group consisting of obesity, cardiovascular disease, and diabetes, and conditions related thereto is provided which comprises extracting peanut shells with a solvent, removing a substantial portion of the solvent to produce a concentrated extract. Phytomedicinal compositions are provided that comprise an effective amount of at least one coumarin compound or one coumarin derivative derived from plant material that modulates a biological activity of at least one enzyme selected from the group consisting of Pancreatic Lipase (PL), Lipoprotein Lipase (LPL), and Hormone-Sensitive Lipase (HSL). Phytomedicinal compositions are provided that comprise at least an effective amount of coumarin derivatives (6,7-dihydroxycoumarin-esculetin, and esculetin-like compounds). A method for the prevention and/or treatment of treatment of a condition selected from the group consisting of obesity, cardiovascular disease, and diabetes, is provided which comprises administering a composition comprising an effective amount of at least one coumarin derivative, including 6,7-dihydroxycoumarin (esculetin), derived from plant material that modulates a biological activity of at least one enzyme selected from the group consisting of Pancreatic Lipase (PL), Lipoprotein Lipase (LPL), and Hormone-Sensitive Lipase (HSL).

The present invention relates to methods and compositions for modulating lipogenesis, lipid accumulation and lipid metabolism in a cell. These methods and compositions modulate genes which are controlled by LXRα, including the lipogenic transcription factor SREBP-1c.

The invention belongs to the field of pharmaceuticals and relates to application of a cyclocarya paliurus effective part in preparation of health products and medicines which are used for treating a non-alcoholic fatty liver disease. The cyclocarya paliurus effective part mainly contains natural triterpenoid and can be used for effectively reducing rat liver lipid accumulation degree and triglyceride level which are caused by high fat diet, improving the liver histology and liver functions and improving the liver oxidative stress and the organism inflammatory level, so that the cyclocarya paliurus effective part can be used for obviously alleviating non-alcoholic fatty liver disease and preparing health products and medicines which are used for treating the non-alcohol fatty liver disease. The application of the cyclocarya paliurus effective part has the advantage that application range of cyclocarya paliurus preparation in the medical field.

The invention relates to a method for making a mung bean protein peptide-zinc chelate. Mung bean protein is used as raw material; the raw material is hydrolyzed by alkaline protease to obtain mung bean polypeptide hydrolysate; and after polypeptide in the mung beanpeptide hydrolysate is freeze-dried, the mung bean polypeptide hydrolysate has a chelation reaction with zinc to obtain the mung bean protein peptide-zinc chelate. The method for making the mung bean protein peptide-zinc chelate, provided by the invention, has the advantages that by chelating the mung bean protein peptide and zinc ions and utilizing a characteristic that the mung bean protein small peptides are easily absorbed by intestinal tracts, the zinc absorption of the intestinal tracts and zinc accumulation in the body canbe promoted, the zinc absorption and utilization rate can be increased, and meanwhile, the zinc ions can be prevented from being lost due to precipitating in alkaline intestinal environment, and thezinc ion dissolving rate and the dialysance of the mung bean protein peptide-zinc chelate after being digested in the stomach and intestine are both higher than those of zinc heptahydrate.

Disclosed are applications of Bouchardatine and Bouchardatine derivative in preparation of an anti-obesity and fatty liver-relieving drug. The structural fomulas of the Bouchardatine and the Bouchardatine derivative are shown in a pattern (I), to be specific, R is -(CH<2>)<n>R<1>, R<1>is substituted phenyl, heterocyclic radical or substituted amidogen, and n is equal to 0, 1, 2 or 3. By the use of the Bouchardatine and the Bouchardatine derivative, differentiation of pre-adipocyte 3T3-L1 is restrained so as to reduce lipid accumulation in adipocyte 3T3-L1; lipid accumulation, caused by sodium oleate, in hepatoma carcinoma cells is reduced, zooblast triglyceride level is lowered, and anti-obesity and fatty liver-relieving effect is achieved.

The invention discloses a preparation method and application of cordyceps militaris sporocarp heteropolysaccharide. The preparation method mainly comprises the following steps that cordyceps militaris sporocarp is subjected to drying, pulverization, ethanol degreasing and hot water ultrasonic extraction, and an extracting solution is subjected to concentration, alcohol precipitation, deproteinization, column chromatography, dialysis and freeze-drying, so that the cordyceps militaris sporocarp heteropolysaccharide TY258 is obtained. The cordyceps militaris polysaccharide has the efficacy of lowering lipid and resisting to atherosclerosis and can remarkably lower the cholesterol level, the triglyceride level and the low density lipoprotein level of high-fat induced atherosclerosis model mice (mice with apolipoprotein and low density lipoprotein receptors knocked out) and lipid accumulation of the livers and arcus aortae at the concentration of 25 mg/kg, lift the high density lipoprotein cholesterol level of the mice and improve activity of superoxide dismutase and lipoprotein esterolysis enzyme. The cordyceps militaris sporocarp polysaccharide can also remarkably lower the contents of plasma triglyceride, cholesterol, malonaldehyde and oxidized low-density lipoprotein of high-fat induced guinea pigs and rats.

The invention relates to a new application of oleic acid and glycerol 1-monooleate in the preparation of a kit for evaluating the intestinal lipid accumulation in a tested organism and its intervention effect, and a detection method of the oleic acid and the glycerol 1-monooleate. A reagent and the method are used to detect the content of the oleic acid and the glycerol 1-monooleate in the intestinal tissues of the tested organism. The invention further provides the method for detecting the content of the oleic acid and the glycerol 1-monooleate in the intestinal tissues of the tested organismthrough gas chromatography-mass spectrometry. The content can be used for evaluating the intestinal lipid accumulation and its intervention effect. The kit and the detection method have the characteristics of simplicity in operation, good reliability, fastness, high sensitivity, high specificity, and easiness in promotion.

The invention discloses an application of a celastrus orbiculatus alcohol extract in preparing a medicine for treating non-alcoholic fatty liver disease (NAFLD). By adopting a high-fat diet induced guinea pig NAFLD model and taking simvastatin as a positive control medicine, the celastrus orbiculatus alcohol extract is orally taken for 8 weeks, then influence of the celastrus orbiculatus alcohol extract on NAFLD is observed, and a corresponding mechanism is explored; and the result indicates that the celastrus orbiculatus alcohol extract can be used for obviously improving the high-fat induced pathological alteration of liver tissue, easing the damage of liver cells, reducing the lipid accumulation in liver and suppressing oxidative stress reaction in liver. According to the invention, a new application of the celastrus orbiculatus alcohol extract is developed, and a new means of treating NAFLD is provided.

The invention provides a method and a system for producing heterotrophic alga in high density. In the method, unique biological characteristics of a microbial system are utilized, and the accumulation of lipid is increased by simulating cell division and the uncoupling of cell growth/amount. A process for producing polyunsaturated fatty acid (PUFA) by microalgae fermentation comprises three different stages: (1) a cell proliferation stage for increasing the number of cells; (2) a biomass and lipid accumulation stage for increasing cell biomass, particularly the amount of the lipid; and (3) a lipid concentration increasing stage by refining for producing more PUFA by adjusting the steering of the lipid. Various variables such as the types and concentration of a carbon source and nutritional factors, dissolved oxygen and temperature are changed continuously through a three-stage alga growing process to produce maximum biomass, lipid and docosahexaenoic acid (DHA) by final induction. Therefore, most cell viability leads to the cell division and the rapid formation of a large number of cells, so that the biomass and the lipid yield are integrally enhanced finally.

The invention discloses a liver protection effect and application of sulforaphen in non-alcoholic fatty liver, and belongs to the fields of biomedicine and food. According to the invention, the sulforaphen can be used for effectively treating liver diseases and decelerating lipid accumulation and steatosis of the liver, has the effect of obviously decelerating non-alcoholic fatty liver, and can reduce the glutamic-pyruvic transaminase and glutamic-oxaloacetic transaminase levels in blood, thereby opening a new way to treat fatty liver diseases and liver function impairment, having important meanings for development of edible and medicinal dual-purpose resources, realizing high-value transformation of active plant resources and promoting fine and deep processing and utilization of agricultural products. The sulforaphen having a liver protection effect can be widely used in the fields of food, medicine and the like, and has obvious social benefits and economic benefits.

The invention provides an application of GGPPS serving as a target for treating non-alcoholic fatty liver disease. A GGPPS antagonist disclosed by the invention can reduce genetic expression related to lipid accumulation of the liver. The liver-specific knockout GGPPS disclosed by the invention is capable of retarding the lipid accumulation and degeneration of the liver, reducing the level of aspartate transaminase (AST) and alanine aminotransferase (ALT) and protecting the liver functions.

The present invention relates to uses of hesperidin or hesperetin for inhibiting the activity of acyl CoA-cholesterol-o-acyltransferase, inhibiting the accumulation of macrophage-lipid complex on the arterial endothelium, and preventing or treating hepatic diseases in a mammal.